Search through
Tenofovir Disoproxil (CAS 201306-15-2) is a cornerstone in the US API intermediates market, primarily utilized for the synthesis of tenofovir disoproxil fumarate, where a Pharma/API purity of 99% is vital to ensure compliance with stringent FDA and American Chemical Society standards. Bis(POC)PMPA has seen a significant surge in demand through custom synthesis services as United States-based CDMOs expand their manufacturing capacity to support the domestic production of antiretroviral therapies and chronic hepatitis B treatments. TDF precursor molecules are increasingly prioritized by every leading bulk chemical supplier in the region as part of a broader strategic shift to onshore high purity fine chemicals and mitigate the risks associated with global sourcing and supply chain disruptions. We are an established Tenofovir Disoproxil api supplier with >= 99% purity for semi-finished formulators in the united states, providing comprehensive analytical (HPLC/NMR/MS) and supporting (Tenofovir Disoproxil) COA/TDS/SDS region-specific regulatory support. reliable lead times, worldwide supply chain capabilities
Tenofovir Disoproxil (CAS 201306-15-2) is a cornerstone in the US API intermediates market, primarily utilized for the synthesis of tenofovir disoproxil fumarate, where a Pharma/API purity of 99% is vital to ensure compliance with stringent FDA and American Chemical Society standards. Bis(POC)PMPA has seen a significant surge in demand through custom synthesis services as United States-based CDMOs expand their manufacturing capacity to support the domestic production of antiretroviral therapies and chronic hepatitis B treatments. TDF precursor molecules are increasingly prioritized by every leading bulk chemical supplier in the region as part of a broader strategic shift to onshore high puri...
.3d8f8f41.svg)
Pharmaceutical
.3556d45a.svg)
Pharmaceutical Actives & Precursors
Active Pharmaceutical Ingredients (APIs)
.7767eb0f.png)
Chemical Properties & Specifications
P264, P270, P280, P302+P352, P305+P351+P338, P310, P321, P332+P313, P362, P405, and P501
Acute Tox. 4 (100%)
Skin Irrit. 2 (100%)
Tenofovir disoproxil fumarate is a nucleotide reverse transcriptase inhibitor (NRTI) used in combination with other antiretroviral agents to manage HIV-1 infection in adults and pediatric patients at least 2 years of age
The medication is indicated for the treatment of chronic hepatitis B virus (HBV) infection in both adults and pediatric patients, working by inhibiting the viral DNA polymerase enzyme to reduce viral load
When used in fixed-dose combinations with emtricitabine, it is utilized for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk individuals
Served as a critical advancement in antiretroviral therapy as a prodrug of tenofovir, designed to improve oral bioavailability and membrane permeability for more effective intracellular delivery.
TENOFOVIR DISOPROX, or Tenofovir disoproxil fumarate, is a nucleotide analog reverse transcriptase inhibitor (NtRTI) used to treat HIV-1 infection and chronic hepatitis B
This ingredient is primarily used in the pharmaceutical and healthcare industries for the production of antiviral medications
It is compatible with oral dosage forms such as film-coated tablets and oral powders, as well as experimental gel formulations for microbicides
Standard analytical specifications include CAS number 202138-50-9, high purity (typically ≥98%), and documentation such as COA, TDS, impurity reports, and regulatory compliance documents
Scimplify has capabilities for global distribution and custom synthesis through an integrated network of manufacturers and logistics partners with reliable lead time
The product is export ready with a standard MOQ starting from 100 kgs, with lead times for international customers depending on the specific formulation and destination.
Category : Pharmaceutical Actives & Precursors
Sub-Category : Intermediates & Precursors
Description : P-Nitrobenzoyl Chloride (CAS 122-04-3) is a critical building block in the API intermediates market,...
